Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Yarrow Bioscience Q3 2026 Results: Net Loss of $9.72M

Yarrow Bioscience, Inc. reported a net loss of $9.7 million for the third quarter of 2026, driven by $10.7 million in operating expenses. Following a merger, the company significantly strengthened its balance sheet, ending the period with $268.9 million in cash and cash equivalents compared to $100.0 million at the end of 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Net income-9.7—
EPS (diluted, $ a share)$-0.43—

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: YARW. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Yarrow Bioscience, Inc.: key numbers

Share price
$13.93Close, Nov 16
Market cap
$212M
Shares outstanding
15.23MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Yarrow Bioscience, Inc.

All →
7:08 AM ET 8-K
Financial Results

Yarrow Bioscience Financial Results

Yarrow Bioscience reported third quarter 2026 financial results, ending the period with $268.9 million in cash following a $172.5 million public offering. The company is currently enrolling patients in its Phase 2a/2b DIRECTION-GD trial for YB-101, with topline data expected in the second half of 2027.

“We made significant progress in the third quarter, including dosing our first patient in the Phase 2a portion of the DIRECTION-GD trial and strengthening our balance sheet through the completion of our merger and subsequent public offering. The financing extends our expected cash runway into 2030 and positions us to advance YB-101 in Graves’ disease and prepare for our next steps in thyroid eye disease.”

Rebecca V. Frey, PharmD, President and Chief Executive Officer
4:02 PM ET 8-K
Capital Raise

Yarrow Bioscience Capital Raise of $172M

Yarrow Bioscience entered into an underwriting agreement to sell 5,769,231 shares of common stock at $26.00 per share. The underwriters fully exercised their option to purchase an additional 865,384 shares, bringing the total expected net proceeds to approximately $161.8 million after expenses.

Value
$172M
Counterparty
Jefferies LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.